Abstract 4027: TSN084, a multi-kinase inhibitor, overcomes acquired drug-resistant mutations of cMet, Trks, and Flt3, and displays broad activities against kinase oncotargets Axl, DDRs, and CDK8/19
Zhong, Boyu, Zhang, Tony, Dong, Chunlan, Mark Ma, Shengtang, Jia, Ziyang, Chen, Guangming, Zheng, Renjuan, Li, Jing Cindy, Fu, Han
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article